Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide starts acting in your body within hours of the first injection, but meaningful appetite changes typically arrive within one to two weeks, and noticeable weight loss usually follows over the first four to twelve weeks. Most people lose measurable weight within the first month, with results building steadily across the treatment programme. These are prescription-only medicines: a GPhC-registered prescriber assesses your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, measurably, even if you can't feel it yet. Once tirzepatide is absorbed after a subcutaneous injection, it binds to GIP and GLP-1 receptors within hours. Gastric emptying slows. Appetite-regulating signals in the brain begin to shift. For some people, hunger feels a little different within the first few days. Others notice nothing at all at 2.5 mg, which is entirely normal.
The 2.5 mg opening dose exists to give your digestive system time to adapt, not because it is the effective treatment dose. Nausea and other gastrointestinal effects are most likely to appear at the start or after a dose increase, keeping the initial dose low reduces that risk considerably. So if your first few weeks feel unremarkable, that is the plan working. The full Mounjaro overview on our site explains the titration schedule in plain terms if you want the bigger picture.
The NHS notes that tirzepatide's most common early side effects are gastrointestinal (nausea, loose stools, indigestion) and that these tend to ease as the body settles in. Reviewing the NHS tirzepatide medicine page before you start is a useful habit.
The honest answer: somewhere between two and eight weeks for the first change on the scales, with the clearest progress appearing across the first three months as the dose increases. If you want to understand the timeline in more detail, our page on how long tirzepatide takes to work walks through what to expect at each stage. Many people describe eating less without feeling like they are dieting, finishing meals earlier, forgetting to snack, losing the habit of eating past fullness. The calorie reduction that follows is where the weight loss comes from.
Clinical trial data gives us the best available yardstick. In SURMOUNT-1, published in the New England Journal of Medicine, participants on tirzepatide 15 mg lost an average of around 20–21% of body weight over 72 weeks. That is not a six-week result, it reflects a cumulative process that accelerates as the dose reaches therapeutic levels and lifestyle changes compound over time.
Broadly, most people on a titrated schedule see their most rapid rate of loss between months two and six. Weight loss tends to slow as the body approaches a new set point, which is a physiological response, not treatment failure. If you want cost and access context alongside efficacy, our Mounjaro pricing page covers what to expect from private treatment.
Several things. Starting body weight matters: people with a higher BMI often see larger absolute numbers on the scales early on, though percentage losses may be similar. The dose you are currently on matters more than almost anything else, 2.5 mg and 15 mg are doing meaningfully different amounts of work.
Consistency is significant too. Tirzepatide has a half-life of around five days, which means missing a weekly injection or taking it later than usual reduces the steady concentration in your system. A once-weekly routine (same day, same time) keeps levels stable. Our guide to how long before tirzepatide starts working covers the practical side of maintaining that consistency in more detail.
Diet and activity alongside treatment also shape the rate of progress. Tirzepatide reduces appetite; it does not replace the nutrition your body needs. Adequate protein, hydration, and some form of movement help preserve muscle while fat is lost, which affects how results look and feel over time. A prescriber or dietitian can advise on the specifics for your situation.
Six months is the formal clinical checkpoint. NICE's guidance on tirzepatide (published as technology appraisal TA1026) notes that if a person has not lost at least 5% of body weight after six months at the highest tolerated dose, continuing treatment should be reviewed. That threshold is a safety net, not a target: many people exceed it well before six months.
If you are a few weeks in and feeling uncertain, that is worth raising sooner rather than waiting. A question our prescribers hear regularly is how long after taking Mounjaro it starts working, and the answer usually reassures people that slow early progress means the dose has not yet reached the level where full appetite suppression kicks in, which is simply a matter of time on the titration schedule.
At nume, every repeat order goes back to a clinical reviewer before dispatch, there is no automated approval at any stage. If something feels off, our support team is reachable seven days a week, and a prescriber can assess whether an adjustment makes sense. If you are ready to start or want to discuss your situation before committing, starting a free consultation is the first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.